Literature DB >> 32851421

CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.

Joelle Choueiry1,2,3, Crystal M Blais4, Dhrasti Shah5, Dylan Smith6,7,5, Derek Fisher8, Vadim Illivitsky6, Verner Knott9,6,7,4,5.   

Abstract

RATIONALE: The combination of CDP-choline, an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist, with galantamine, a positive allosteric modulator of nAChRs, is believed to counter the fast desensitization rate of the α7 nAChRs and may be of interest for schizophrenia (SCZ) patients. Beyond the positive and negative clinical symptoms, deficits in early auditory prediction-error processes are also observed in SCZ. Regularity violations activate these mechanisms that are indexed by electroencephalography-derived mismatch negativity (MMN) event-related potentials (ERPs) in response to auditory deviance. OBJECTIVES/
METHODS: This pilot study in thirty-three healthy humans assessed the effects of an optimized α7 nAChR strategy combining CDP-choline (500 mg) with galantamine (16 mg) on speech-elicited MMN amplitude and latency measures. The randomized, double-blinded, placebo-controlled, and counterbalanced design with a baseline stratification method allowed for assessment of individual response differences.
RESULTS: Increases in MMN generation mediated by the acute CDP-choline/galantamine treatment in individuals with low baseline MMN amplitude for frequency, intensity, duration, and vowel deviants were revealed.
CONCLUSIONS: These results, observed primarily at temporal recording sites overlying the auditory cortex, implicate α7 nAChRs in the enhancement of speech deviance detection and warrant further examination with respect to dysfunctional auditory deviance processing in individuals with SCZ.

Entities:  

Keywords:  CDP-choline; Deviance detection; Event-related potentials; Galantamine; MMN; Positive allosteric modulator; Schizophrenia; Sensory memory; α7 nAChR

Mesh:

Substances:

Year:  2020        PMID: 32851421     DOI: 10.1007/s00213-020-05646-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  102 in total

1.  Impairment in frontal but not temporal components of mismatch negativity in schizophrenia.

Authors:  Torsten Baldeweg; Anthony Klugman; John H Gruzelier; Steven R Hirsch
Journal:  Int J Psychophysiol       Date:  2002-02       Impact factor: 2.997

2.  Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.

Authors:  Robert Aidelbaum; Alain Labelle; Ashley Baddeley; Verner Knott
Journal:  J Psychopharmacol       Date:  2018-01-17       Impact factor: 4.153

3.  Premorbid functioning, cognitive functioning, symptoms and outcome in schizophrenia.

Authors:  J Addington; D Addington
Journal:  J Psychiatry Neurosci       Date:  1993-01       Impact factor: 6.186

4.  Improved p50 auditory gating with ondansetron in medicated schizophrenia patients.

Authors:  Lawrence E Adler; Ellen M Cawthra; Kara A Donovan; Josette G Harris; Herbert T Nagamoto; Ann Olincy; Merilyne C Waldo
Journal:  Am J Psychiatry       Date:  2005-02       Impact factor: 18.112

5.  Nicotinic modulation of human auditory sensory memory: Evidence from mismatch negativity potentials.

Authors:  Torsten Baldeweg; Davina Wong; Klaas E Stephan
Journal:  Int J Psychophysiol       Date:  2005-11-28       Impact factor: 2.997

6.  Sensorimotor gating and spatial learning in α7-nicotinic receptor knockout mice.

Authors:  E Azzopardi; M Typlt; B Jenkins; S Schmid
Journal:  Genes Brain Behav       Date:  2013-04-10       Impact factor: 3.449

7.  Contribution of nicotinic receptors to the function of synapses in the central nervous system: the action of choline as a selective agonist of alpha 7 receptors.

Authors:  E X Albuquerque; E F Pereira; M F Braga; M Alkondon
Journal:  J Physiol Paris       Date:  1998 Jun-Aug

8.  Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.

Authors:  Lawrence E Adler; Ann Olincy; Ellen M Cawthra; Kara A McRae; Josette G Harris; Herbert T Nagamoto; Merilyne C Waldo; Mei-Hua Hall; Amanda Bowles; Laurie Woodward; Randal G Ross; Robert Freedman
Journal:  Am J Psychiatry       Date:  2004-10       Impact factor: 18.112

9.  Mismatch negativity potentials and cognitive impairment in schizophrenia.

Authors:  Torsten Baldeweg; Anthony Klugman; John Gruzelier; Steven R Hirsch
Journal:  Schizophr Res       Date:  2004-08-01       Impact factor: 4.939

Review 10.  Synaptic interactions and inhibitory regulation in auditory cortex.

Authors:  Caitlin E Askew; Raju Metherate
Journal:  Biol Psychol       Date:  2015-11-07       Impact factor: 3.251

View more
  1 in total

Review 1.  Bioactive Compounds and Their Derivatives: An Insight into Prospective Phytotherapeutic Approach against Alzheimer's Disease.

Authors:  Fahadul Islam; Jannatul Fardous Khadija; Md Harun-Or-Rashid; Md Saidur Rahaman; Mohamed H Nafady; Md Rezaul Islam; Aklima Akter; Talha Bin Emran; Polrat Wilairatana; Mohammad S Mubarak
Journal:  Oxid Med Cell Longev       Date:  2022-04-11       Impact factor: 7.310

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.